Nausea and vomiting · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes gastrointestinal toxicity (nausea and vomiting)№ of participants:… compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.65 [0.12, 3.66]
Studies not reported
Very low
Neurotoxicity · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
It is very uncertain whether leuprorelin changes neurotoxicity№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).
1 finding from 1 review
RR 0.32 [0.01, 7.71]
Studies not reported
Very low
Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Physical well‐being SF‐36 Physical Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Immediately post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Physical well‐being SF‐36 Physical Component Summary Score 0‐100, higher scores indicate higher levels of physical well‐being Two‐months post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Psychological well‐being SF‐36 Mental Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Immediately post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Psychological well‐being SF‐36 Mental Component Summary Score 0 to 100, higher scores indicate higher levels of physical well‐being Two‐months post‐intervention · Cancer patients with cognitive impairment due to systemic cancer treatment
1 finding from 1 review
Intervention not reported
Estimated total blood loss (mL) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in estimated total blood loss (mL) (low certainty).
1 finding from 1 review
Intervention not reported
Number of transfused units of red blood cell (RBC) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in number of transfused units of red blood cell (RBC) (low certainty).
1 finding from 1 review
Intervention not reported
Number of transfused units of plasma · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in number of transfused units of plasma (low certainty).
1 finding from 1 review
Intervention not reported
Rate of RBC transfusion (total number of participants who required at least one unit of red blood cell transfusion) Time: perioperative and postoperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in rate of RBC transfusion (total number of participants who required… (low certainty).
1 finding from 1 review
Intervention not reported
Rate of plasma transfusion (total number of participants who required at least one unit of plasma transfusion) Time: perioperative and postoperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
The intervention showed no clear difference in rate of plasma transfusion (total number of participants who… (low certainty).
1 finding from 1 review
Intervention not reported
Reoperation (Number of participants with at least one reoperation) Time: perioperative periods · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes reoperation (Number of participants with at least one reoperation)… (very low certainty).
1 finding from 1 review
Intervention not reported
Readmission (Number of participants with at least one readmission) Time: perioperative periods) · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes readmission (Number of participants with at least one readmission)… (very low certainty).
1 finding from 1 review
Intervention not reported
Venous thromboembolic events (number of participants with at least one venous thromboembolic events) Time: 5‐week · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes venous thromboembolic events (number of participants with at least… (very low certainty).
1 finding from 1 review
Intervention not reported
Arterial thromboembolic events (number of participants with at least one venous thromboembolic events) Time: 5‐week · adult women with advanced EOC undergoing cytoreductive surgery (one randomised trial available)
It is very uncertain whether the intervention changes arterial thromboembolic events (number of participants with at least… (very low certainty).
1 finding from 1 review
Response to treatment at 5 to 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ overall response compared with placebo (high certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ complete response compared with cidofovir (moderate certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in pain ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Fatigue · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher fatigue ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review